Fizazi K, et al. - In men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (mCSPC), significant improvement in overall survival and radiographic progression-free survival were reported with the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) vs placebos plus ADT in the interim analyses of the LATITUDE study, so here researchers looked at long-term survival outcomes and safety of abiraterone acetate plus prednisone and ADT reported from the final analysis. Outcomes revealed the achievement of significantly longer overall survival in correlation with the combination of abiraterone acetate plus prednisone with ADT vs placebos plus ADT with a manageable safety profile in these men. Findings thereby support that in patients with high-risk mCSPC, abiraterone acetate plus prednisone should be used as a standard of care.